Galecto Appoints New COO and CMO Effective January 5, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Galecto announced the appointment of Sherwin Sattarzadeh, former Chief Business Officer of Blueprint Medicines Corporation, as Chief Operating Officer, COO, and Dr. Becker Hewes, former Chief Medical Officer of Blueprint Medicines, as Chief Medical Officer, CMO, effective January 5, 2026.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on GLTO
Wall Street analysts forecast GLTO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLTO is 41.00 USD with a low forecast of 36.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 24.450
Low
36.00
Averages
41.00
High
46.00
Current: 24.450
Low
36.00
Averages
41.00
High
46.00
About GLTO
Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Galecto Appoints New Executives to Advance DMR-001 Clinical Trials
- Executive Appointments: Galecto has appointed Sherwin Sattarzadeh as COO and Becker Hewes as CMO, both from Blueprint Medicines, leveraging their 20+ years of drug development experience to drive DMR-001 into clinical trials.
- Clinical Advancement: DMR-001, a monoclonal antibody targeting mutant calreticulin, is on track for IND submission in mid-2026, with plans for first-in-human dosing via subcutaneous administration, marking a significant step in blood cancer treatment.
- Financial Position: The company's cash balance, including $285 million raised in a PIPE in November 2025, provides a financial runway into 2029 to support multiple data milestones, including Phase 1 clinical proof-of-concept data for DMR-001 expected in 2027.
- Incentive Plan: The appointments of Sattarzadeh and Hewes come with stock incentive grants of 190,376 and 264,629 restricted stock units respectively, reflecting the company's commitment to its executive team and confidence in future growth.

Continue Reading
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.

Continue Reading








